About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Group 1: Earnings Performance - Eli Lilly reported quarterly earnings of $1.18 per share, missing the Zacks Consensus Estimate of $1.52 per share, representing an earnings surprise of -22.37% [1] - The company posted revenues of $11.44 billion for the quarter ended September 2024, missing the Zacks Consensus Estimate by 4.92%, compared to year-ago revenues of $9.5 billion [2] - Over the last four quarters, Eli Lilly has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Group 2: Stock Performance and Outlook - Eli Lilly shares have increased approximately 55% since the beginning of the year, outperforming the S&P 500's gain of 22.3% [3] - The sustainability of the stock's immediate price movement will depend on management's commentary on the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the coming quarter is $5.52 on revenues of $14.15 billion, and for the current fiscal year, it is $13.76 on revenues of $46.25 billion [7] Group 3: Industry Context - The Large Cap Pharmaceuticals industry, to which Eli Lilly belongs, is currently in the top 23% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Eli Lilly (LLY) shares tumbled 10% after its third-quarter results fell well short of analysts' estimates before the bell Wednesday. The pharmaceutical giant registered $11.44 billion in revenue—above last year's $9.50 billion but below the $12.18 billion consensus estimate of analysts polled by Visible Alpha—as weight-loss drugs Mounjaro and Zepbound continue to boost Eli Lilly's sales. Lilly swung to a profit of $970.3 million, or $1.07 per share, but still well below the $1.69 billion and $1.87 per shar ...

Oct. 30, 2024 For release: Immediately Refer to: Jordan Bishop; jordan.bishop@lilly.com; (317) 374-1878 (Media) Joe Fletcher; jfletcher@lilly.com; (317) 296-2884 (Investors) Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products • Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue fro ...

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter and slashed its full-year adjusted profit guidance, sending its stock tumbling roughly 10%.The drugmaker now expects full-year adjusted earnings of between $13.02 to $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%. Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.0 b ...

Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. For the past couple of years, two of the biggest themes fueling the stock market to new highs are breakthroughs in the weight loss market and euphoria around artificial intelligence (AI). What if I told you that there's a company that operates across both of these opportunities, and that despite a 61% gain in its share price during the past year, the stock is still a compelling buy? Let's explore what's fu ...

Eli Lilly (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively.The strong sales performance of its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound, helped Lilly deliver exceptionally strong results in the last report quarter. We expect the trend to continue in the third quarter.Tirzepatide is a dual GIP and GLP-1 receptor ...

Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m. ET.Is A Stock Split On The Horizon For This Weight Loss Drug Maker?The stock is up 58.31% over the past year, 51.23% YTD. Eli Lilly’s stock has experienced a remarkable rise, recently trading close to $900 a share, down from a record high of about $972. This surge, especially from just $250 two years ago, positions Lilly for a poten ...

One key disease-prevention market is drawing closer to being within reach. As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.32%) and Novo Nordisk (NVO -0.90%), there's now one more big reason to expect these two stocks to keep climbing. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two companies is making significant headway, so it won't be much longer in the grand scheme of things. Here's ...